MHRA Approves XEVUDY® (sotrovimab), GlaxoSmithKline and Vir Biotechnology's Monoclonal Antibody Treatment for Patients with COVID‑19
MIAMI, Dec. 7, 2021 /PRNewswire/ -- Brand Institute is proud to announce its successful partnership with GlaxoSmithKline and Vir Biotechnology in developing the brand name XEVUDY®, a monoclonal antibody therapeutic approved for symptomatic adults and adolescents (12 years of age and older) with acute COVID–19 infection. XEVUDY® reduces the risk of hospitalization and death by 79% in high-risk adults with symptoms, based on clinical data.
"The entire Brand Institute and Drug Safety Institute Team congratulates GSK and Vir Biotechnology on the MHRA approval of XEVUDY®," said Brand Institute's Chairman and CEO, James L. Dettore. "XEVUDY® will surely be an important treatment option in the global fight against COVID-19."
The U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) is the first health agency to approve XEVUDY®. Approval of the product and the brand name by other regulatory agencies will follow their respective guidelines, policies and procedures.
About Brand Institute and our wholly owned subsidiary, Drug Safety Institute
Brand Institute is the global leader in pharmaceutical and healthcare-related name development, with a portfolio of over 3,500 marketed healthcare names for nearly 1,000 clients. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally every year. Drug Safety Institute is comprised of former naming regulatory officials from global government health agencies, including FDA, EMA, Health Canada, American Medical Association (AMA), and the World Health Organization (WHO). These regulatory experts co-authored the name review guidelines while with their respective agencies, with many responsible for ultimately approving (or rejecting) brand name applications. Now working for a private company, these professionals provide Brand Institute's clients with industry-leading guidance pertaining to drug name safety (i.e., preventing medication errors), packaging, and labeling.
Contact: Scott Piergrossi
View original content to download multimedia:https://www.prnewswire.com/news-releases/mhra-approves-xevudy-sotrovimab-glaxosmithkline-and-vir-biotechnologys-monoclonal-antibody-treatment-for-patients-with-covid19-301439081.html
SOURCE Brand Institute, Inc.